Nursing · Independent exam preparation
CARN Preparation Guide: Assessment, Acute Care, and Recovery Study Guide
Practise substance use assessment, overdose and withdrawal decisions, medication safety, behavior change, and recovery care across the 2026 CARN domains.
By CertMedbry · Updated 27 October 2026
Practise distinguishing overdose from withdrawal, interpreting screening results, recognizing medication hazards, and choosing nursing actions that support continued recovery. This guide develops 60 selected clinical concepts across the five CARN practice domains, followed by independent questions and recall cards. The official 2026 CARN outline defines the full examination scope; this selective guide does not replace it.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
How many questions are on the CARN examination, and how many are scored?
The January 2026 handbook describes 150 multiple-choice questions, including approximately 25 unscored pilot questions. This implies approximately 125 scored questions; the pilot count is approximate, so it should not be presented as an exact guaranteed split.
How long is the examination, and how is it delivered?
The handbook specifies a three-hour examination. C-NET lists year-round computer-based testing, with eligible candidates scheduling a date, time, and location within a 90-day testing window.
CARN Examination Handbook — Revised January 2026 · C-NET — Certified Addictions Registered Nurse
Which item styles are verified?
The handbook identifies multiple-choice questions. The questions in this guide are four-option, single-best-answer learning drills; they do not simulate adaptive testing or predict a passing result.
Which blueprint applies to this guide?
The CARN blueprint was updated in 2025 and implemented in 2026. The handbook is revised January 2026. The blueprint identifies the implementation year without specifying a precise effective day.
ANCB — Statistics & Studies · CARN Test Specifications (Blueprint) — Implemented 2026 · CARN Examination Handbook — Revised January 2026
How are the practice domains weighted?
The official practice weights are biopsychosocial SUD assessment 15%; acute care needs 20%; individualized planning 15%; education and behavioral change 15%; and care management, treatment, and evaluation throughout the recovery continuum, including special populations, 35%. The 60 concepts follow a 9/12/9/9/21 distribution. Both the questions and flashcards follow a 3/4/3/3/7 distribution.
How does the patient-problem axis affect preparation?
The blueprint also weights opioid use disorder 27%; alcohol use disorders 25%; medication misuse 10%; co-occurring psychiatric or comorbid medical disorders 12%; stimulant use disorders 15%; cannabinoids and other hallucinogens 6%; and tobacco use disorder 5%. These categories cross the practice domains. Medication misuse includes sedatives, hypnotics, anxiolytics, and gabapentinoids. Co-occurring content includes process addictions, infectious diseases, and mental health disorders. The official outline remains the full scope, including topics receiving limited treatment in this selective guide.
Who awards CARN, and how does it differ from CARN-AP?
The Addictions Nursing Certification Board awards CARN; C-NET is the testing agency. CARN is the registered nurse pathway. CARN-AP is a separate advanced practice credential, and its eligibility requirements and blueprint should not be substituted for CARN preparation. ANCB states that it certifies nurses in the United States and Canada; certification does not replace jurisdictional nursing licensure.
ANCB — Home · C-NET — Certified Addictions Registered Nurse · CARN Examination Handbook — Revised January 2026
Are the alcohol measures and clinical references jurisdiction-specific?
Several clinical references are United States sources. In particular, the standard-drink calculation uses the NIAAA United States definition of 14 grams of pure alcohol. Apply local nursing scope, prescribing authority, emergency procedures, and public health requirements in practice; CARN certification does not create a universal legal scope.
NIAAA — What Is a Standard Drink? · C-NET — Certified Addictions Registered Nurse
This guide addresses ANCB's Certified Addictions Registered Nurse (CARN), the registered nurse credential. Certified Addictions Registered Nurse-Advanced Practice (CARN-AP) is a separate credential with a separate blueprint. The singular wording Certified Addiction Registered Nurse refers here to the same CARN listing, without implying a separate examination or documented historical renaming. These are independently authored learning materials, not official examination questions or issuer-endorsed preparation.
Outline used: CARN Test Specifications (Blueprint), updated in 2025 and implemented in 2026; CARN Examination Handbook revised January 2026. Verified on 2026-10-10. The workbook's singular wording, Certified Addiction Registered Nurse, maps to the current officially named Certified Addictions Registered Nurse (CARN); the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Perform a biopsychosocial SUD assessment15%
1.What establishes opioid use disorder beyond opioid exposure?
Opioid use disorder requires a problematic pattern causing clinically significant impairment or distress, with at least two diagnostic criteria occurring within 12 months. Assess impaired control, craving, hazardous use, role disruption, and continued use despite harm rather than inferring a disorder from exposure alone. Two or three criteria indicate mild severity, four or five moderate severity, and six or more severe severity. A prescription or positive toxicology result alone does not establish the diagnosis.
Apply it
A patient reports repeated unsuccessful efforts to stop nonprescribed oxycodone, strong cravings, and missed work because of use. Organize these findings against diagnostic criteria and the 12-month timeframe instead of relying on the urine result.
Common pitfall: Equating any opioid use with addiction misses the required pattern of impairment and can misclassify patients receiving appropriate treatment for pain.
2.When do tolerance and withdrawal count toward opioid use disorder?
Tolerance and withdrawal reflect physiological adaptation and do not automatically demonstrate compulsive opioid use. These two criteria are not counted when opioids are taken solely under appropriate medical supervision. Other criteria still require assessment, including loss of control, unsuccessful efforts to reduce use, and continued use despite consequences. The discriminating issue is the behavioral and functional pattern, not whether the body has adapted to a regularly administered opioid medication over time.
Apply it
A patient taking prescribed opioids as directed develops withdrawal after an interrupted refill but reports no loss of control or related impairment. Document physiological dependence and assess other criteria before concluding that opioid use disorder is present.
Common pitfall: Treating withdrawal after a missed prescription as sufficient proof of opioid use disorder confuses expected adaptation with a broader diagnostic syndrome and risks misclassification.
3.How should a positive alcohol screen change the assessment?
A validated alcohol screen identifies a need for further assessment; it does not independently diagnose alcohol use disorder. Follow a positive result with questions about quantity, frequency, heavy drinking episodes, consequences, impaired control, and withdrawal history. Screening and diagnostic assessment answer different questions: whether risk warrants attention and whether diagnostic criteria are met. Include immediate safety needs before moving into routine counseling, particularly when the person reports recent reduction after prolonged heavy drinking.
Apply it
A patient has a positive AUDIT-C result during a routine visit. Ask about drinking patterns, functional effects, previous withdrawal, and current goals, then determine whether a fuller diagnostic assessment or urgent withdrawal evaluation is needed.
Common pitfall: Labeling every positive screen as alcohol use disorder overstates the tool's purpose and can bypass the assessment needed to select an appropriate response.
4.How are United States standard drinks calculated?
A United States standard drink contains about 14 grams of pure alcohol. Common equivalents are 12 fluid ounces of 5% beer, 5 fluid ounces of 12% wine, or 1.5 fluid ounces of 40% spirits. Container size and alcohol concentration both matter: a large or strong beverage may contain several standard drinks. Convert actual intake before interpreting screening responses or comparing drinking patterns, and identify the national definition being used.
Apply it
A patient calls a 24-ounce can of 5% beer one drink. Using the United States definition, record it as two standard drinks and use that amount when clarifying the patient's usual daily intake.
Common pitfall: Counting containers rather than alcohol content underestimates exposure, especially with large cans, strong beer, generous wine pours, and mixed drinks containing multiple spirit measures.
5.Which injection practices reveal additional infection risks?
Injection assessment should include shared syringes and shared preparation equipment, such as cookers, filters, and water. Bloodborne infection risk is not limited to visibly used needles. Ask neutrally about access to sterile supplies, hepatitis testing, vaccination, and connections to syringe services. This route-specific history identifies prevention opportunities that a substance name or frequency alone cannot reveal. An absence of symptoms does not exclude viral hepatitis or eliminate the need for appropriate testing.
Apply it
A patient says they always use a new syringe but share a cooker and rinse water with friends. Explain that preparation equipment can transmit infection and connect the patient with comprehensive sterile supplies and hepatitis services.
Common pitfall: Stopping after the question about needle sharing overlooks other contaminated equipment and can give false reassurance about hepatitis risk despite continued blood exposure.
6.What medication history predicts benzodiazepine withdrawal risk?
Assess the actual benzodiazepine taken, frequency, duration, recent dose changes, last use, and prior withdrawal experiences. Regular exposure can produce physical dependence even when medication was prescribed and taken as directed. Previous withdrawal seizures, concurrent alcohol use, and other sedating medications can alter risk and care needs. Distinguish physical dependence from a substance use disorder while recognizing that abrupt interruption may still require an urgent, medically supervised response.
Apply it
A patient describes taking a prescribed benzodiazepine every evening for several years and running out yesterday. Clarify previous missed-dose symptoms, seizure history, alcohol intake, and opioid use before treating the interruption as a routine refill issue.
Common pitfall: Assuming a prescribed medication cannot cause dangerous withdrawal overlooks physiological dependence; assuming dependence proves misuse creates a different but equally misleading assessment error.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
7.Which stimulant-history details change immediate triage?
Stimulant assessment links substance, route, timing, amount, and co-use with current cardiovascular, neurological, and psychiatric symptoms. Chest pain, marked agitation, hyperthermia, or psychosis can indicate acute complications requiring prompt evaluation. Also ask about sleep deprivation, recent reduction in use, and suicidal thinking because risk can change as intoxication wanes. A report of anxiety alone should not obscure a possible stimulant-associated medical emergency when accompanying physical findings are concerning.
Apply it
A patient requesting help after methamphetamine use reports no sleep for two nights and intermittent chest pressure. Establish timing and co-use, assess vital signs and mental status, and escalate the chest symptoms for acute evaluation.
Common pitfall: Interpreting stimulant-related symptoms only as behavioral distress can miss cardiovascular toxicity or evolving psychiatric risk during the transition from intoxication to withdrawal and recovery.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
8.How does a psychosocial assessment change an individualized care plan?
Assess previous treatment and outcomes, daily functioning, recovery environment, trusted supports, housing, transportation, and patient priorities alongside medical and psychiatric needs. Identify what helped, why care ended, and which barriers remain. Translate findings into specific services and feasible appointments rather than recording social circumstances without acting on them.
Apply it
A patient seeking stimulant treatment previously improved with counseling but stopped when bus service ended. Work is threatened, housing includes active substance use, a sibling can help, and keeping employment is the priority. Arrange accessible appointment times and transportation, offer housing support, and involve the sibling with permission.
Common pitfall: Calling missed visits poor motivation overlooks whether the treatment plan was practically accessible.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
9.Why does the timeline of mood symptoms matter?
Alcohol intoxication and withdrawal can produce or worsen anxiety, depression, and sleep disturbance, while an independent psychiatric disorder may also be present. Assess symptoms before heavy use, during use, during reductions, and across periods of recovery. This chronology helps the team refine the differential without assuming every symptom is substance-induced. Current suicide risk and functional impairment still require attention immediately; diagnostic uncertainty does not justify postponing safety assessment or treatment engagement.
Apply it
A patient reports depression during heavy drinking but also describes a major depressive episode years before alcohol problems began. Document both timelines, assess suicide risk now, and arrange coordinated evaluation of the alcohol and mood conditions.
Common pitfall: Demanding prolonged abstinence before addressing any psychiatric symptoms can delay essential care; diagnosing solely during intoxication can also misrepresent the person's longer-term condition.
NIAAA — Alcohol Use Disorder and Common Co-occurring Mental Health Conditions
Assess acute care needs of SUD patients20%
10.Which findings make opioid overdose an emergency?
Unresponsiveness with slow, irregular, absent, or gasping breathing signals a suspected opioid emergency. Activate emergency services immediately, give naloxone promptly, and provide indicated breathing or resuscitative support. Naloxone administration must not delay emergency activation or support of breathing and circulation. A person who is not breathing normally requires immediate action rather than observation while waiting for the medication to work. Follow emergency dispatcher instructions and responder training, and use an available AED when cardiac arrest is suspected.
Apply it
An adult is unresponsive with gasping breaths after taking an unknown pill. Call emergency services on speakerphone, begin indicated resuscitative support following dispatcher instructions, and have another person obtain naloxone and an AED if available. Continue reassessment while awaiting responders.
Common pitfall: Gasping, snoring, or gurgling does not establish normal breathing. Waiting for naloxone to work or searching for the exact pill can delay lifesaving support.
11.Why can respiratory depression return after naloxone?
Naloxone temporarily reverses opioid effects, but the opioid may remain active after the reversal medication wears off. Recurrent sedation or respiratory depression therefore remains possible after an apparent recovery. Continue monitoring breathing and responsiveness, maintain emergency evaluation, and give additional reversal medication when indicated by product directions and response. The treatment target is restoration of adequate breathing, not simply waking the person or provoking withdrawal. Initial improvement does not establish that the emergency has ended.
Apply it
A patient breathes more regularly after naloxone, then becomes difficult to awaken again before emergency transport arrives. Reassess breathing, provide indicated support, and repeat naloxone according to directions while keeping emergency responders informed of the change.
Common pitfall: Allowing someone to remain alone after awakening overlooks the mismatch between naloxone duration and opioid duration and leaves recurrent respiratory depression potentially unrecognized and untreated.
12.What predicts complicated alcohol withdrawal?
Previous withdrawal seizures or withdrawal delirium strongly influence alcohol withdrawal risk. Other concerns include repeated withdrawal episodes, prolonged heavy drinking, marked autonomic activity, significant medical illness, and dependence on other sedative substances. Assess history alongside current findings because initially mild symptoms do not guarantee an uncomplicated course. A positive blood alcohol concentration does not exclude withdrawal: symptoms can develop when alcohol exposure falls substantially from the person's accustomed level, even before the concentration reaches zero.
Apply it
A patient with mild tremor has recently reduced heavy daily drinking and previously required intensive care for withdrawal delirium. Escalate the risk assessment and monitoring plan rather than treating the mild present symptoms as reassuring.
Common pitfall: Using a single current symptom score or a detectable alcohol level to dismiss historical risk can miss the patient most likely to deteriorate later.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
13.How should alcohol withdrawal be monitored when delirium makes CIWA-Ar unreliable?
CIWA-Ar depends partly on patient-reported symptoms and should not be used in delirium. Distinguish three monitoring purposes: CAM-ICU assesses delirium; RASS tracks agitation and depth of sedation; MINDS assesses withdrawal severity with less reliance on subjective reporting. These instruments are not interchangeable. Combine the selected assessments with vital signs, oximetry, and cardiac monitoring as indicated. Evaluate other causes of confusion, including infection and medication effects.
Apply it
A confused postoperative patient with fever cannot answer CIWA-Ar questions reliably. Escalate evaluation for delirium causes, assess delirium with CAM-ICU, follow agitation and sedation with RASS, and use a withdrawal instrument such as MINDS within the treatment protocol. An agitated, disoriented patient requires continuous individual observation.
Common pitfall: A RASS score does not diagnose delirium or quantify the entire withdrawal syndrome; a CAM-ICU result does not establish alcohol withdrawal as its cause.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
14.How does alcohol withdrawal delirium change care needs?
Alcohol withdrawal delirium involves disturbed attention and awareness with cognitive change in the withdrawal setting, often accompanied by pronounced autonomic activation. It requires close medical monitoring and treatment, with assessment for additional causes of delirium. Hallucinations alone in an otherwise clear sensorium do not establish delirium. Benzodiazepines are first-line treatment for alcohol withdrawal delirium; antipsychotic medication, when used, is adjunctive rather than a substitute for therapy addressing the underlying withdrawal physiology.
Apply it
A withdrawing patient becomes disoriented, cannot sustain attention, and develops marked diaphoresis and tachycardia. Escalate urgently for medically managed withdrawal and investigation of other delirium causes instead of addressing hallucinations as an isolated psychiatric complaint.
Common pitfall: Selecting an antipsychotic alone because hallucinations are prominent leaves the underlying withdrawal inadequately treated and fails to provide the seizure protection needed in severe withdrawal.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
15.Why is thiamine important during alcohol withdrawal care?
Patients with prolonged heavy alcohol use may have thiamine deficiency, especially with poor nutrition, and require prevention or treatment of related neurological injury. ASAM recommends thiamine during withdrawal management, with parenteral administration preferred in situations such as poor nutritional status or malabsorption. Confusion, gait disturbance, or ocular abnormalities warrant urgent evaluation. If hypoglycemia also requires glucose, do not delay glucose while waiting for thiamine; ASAM permits administration in either order or concurrently.
Apply it
A malnourished patient with heavy alcohol use presents confused and hypoglycemic. Treat the hypoglycemia promptly while arranging thiamine and further assessment, rather than allowing an assumed mandatory medication sequence to postpone correction of the low glucose.
Common pitfall: Assuming the complete classic neurological triad must be present delays recognition; insisting that glucose always wait for thiamine can also delay necessary emergency treatment.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
16.When does benzodiazepine withdrawal require urgent escalation?
Abrupt benzodiazepine discontinuation in a physically dependent person can cause serious withdrawal, including seizures and delirium. Severe confusion, seizure activity, or substantial autonomic instability requires urgent medical evaluation and a setting capable of managing complications. Assess other causes simultaneously rather than attributing every symptom to withdrawal. The immediate decision concerns safety and monitoring intensity; a routine outpatient taper discussion is insufficient when complicated withdrawal is already occurring or is strongly anticipated.
Apply it
A patient who abruptly stopped long-term benzodiazepines develops disorientation and a seizure. Initiate the emergency response and communicate the medication interruption, duration of exposure, and co-used substances to the team managing acute stabilization and monitoring.
Common pitfall: Treating severe symptoms as ordinary rebound anxiety understates the withdrawal syndrome and can lead to an unsafe plan based only on reassurance or routine follow-up.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
17.How should chest pain after stimulant use be evaluated?
Stimulants increase sympathetic activity and can contribute to myocardial ischemia and other cardiovascular emergencies. Chest pain after stimulant use requires assessment for acute coronary syndrome and other dangerous causes, while stimulant intoxication is treated concurrently. Improvement in agitation does not independently exclude cardiac injury. The discriminating cue is chest pain in a potentially cardiotoxic exposure, not whether the patient is young or has a previous anxiety diagnosis. Avoid reducing the presentation to a behavioral problem.
Apply it
A young adult with recent cocaine use reports persistent chest pressure after agitation improves. Continue urgent cardiovascular evaluation and monitoring rather than ending the assessment because calming measures reduced the patient's visible distress and heart rate.
Common pitfall: Attributing chest pain to panic because of age or stimulant use can obscure the very exposure that raises concern for ischemia and other acute complications.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
18.Why is stimulant-associated hyperthermia dangerous?
Severe stimulant intoxication can combine agitation, sustained muscular activity, and impaired temperature regulation, producing dangerous hyperthermia. High temperature with severe agitation requires rapid medical stabilization, temperature management, and assessment for complications such as rhabdomyolysis and organ injury. A quiet environment may reduce stimulation but does not replace acute treatment when physiological instability is present. Monitor the body and the behavior together; apparent psychiatric agitation can accompany a rapidly escalating systemic emergency.
Apply it
A patient after methamphetamine use is extremely agitated, hot, and tachycardic. Activate acute medical management, obtain objective temperature and physiological monitoring, and support prescribed cooling and agitation treatment while evaluating for muscle injury and other complications.
Common pitfall: Focusing only on controlling disruptive behavior can leave hyperthermia and organ injury untreated, even when the patient briefly appears calmer after initial de-escalation measures.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
19.When can suicide risk rise after stimulant intoxication?
Psychiatric risk can change as stimulant intoxication wanes and withdrawal begins. Dysphoria, depression, exhaustion, and suicidal thinking may emerge or intensify after visible agitation has settled. Reassess mental status and suicide risk during this transition instead of considering physiological calming sufficient for discharge. Distinguish temporary improvement in observable behavior from sustained safety. Persistent psychosis, severe depression, or suicidal intent requires treatment and a disposition matched to the current risk and available supports.
Apply it
A patient initially agitated after stimulant use becomes quiet several hours later and says life is no longer worth living. Repeat suicide assessment and revise the safety plan and disposition instead of interpreting quietness as uncomplicated recovery.
Common pitfall: Assuming the end of agitation marks the end of danger overlooks a transition during which depressive symptoms and suicide risk may become more apparent or intensify.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
20.What response follows current suicidal thoughts?
Current suicidal thoughts require immediate assessment of intent, plan, access to means, prior behavior, and the person's ability to remain safe. NIMH identifies current suicidal thoughts during assessment as requiring urgent mental health evaluation; the patient should not be left alone. Use a collaborative safety plan for appropriate ongoing care, including warning signs, coping strategies, contacts, and means safety. A promise or safety contract does not replace assessment, observation, or indicated emergency evaluation.
Apply it
During an outpatient substance use visit, a patient reports suicidal thoughts occurring now and access to a firearm. Maintain supervision, arrange urgent evaluation, and address access to lethal means through the clinical safety response and available supports.
Common pitfall: Obtaining a promise not to self-harm and proceeding with routine discharge mistakes verbal reassurance for an adequate assessment and response to current suicide risk.
NIMH — Adult Outpatient Brief Suicide Safety Assessment Guide
21.How should reported hallucinogen exposure affect assessment of acute perceptual disturbance?
A reported hallucinogen exposure is part of the history, not a complete explanation for agitation or perceptual disturbance. Establish the reported substance, timing, co-use, attention, orientation, vital signs, and injury or suicide risk. Altered consciousness, seizure, hyperthermia, or severe agitation requires acute medical evaluation. A negative routine toxicology screen means the targeted substances or metabolites were not detected above the assay cutoff in that sample. It does not rule out exposure, intoxication, or substances absent from the panel. Interpret results alongside clinical findings, exposure timing, and assay limitations; obtain targeted or definitive testing when clinically indicated.
Apply it
A patient becomes agitated and disoriented after taking a substance described as a hallucinogen, but the routine toxicology screen is negative. Continue assessing physiological stability and alternative causes. Review which substances the panel targets and when the sample was collected: collection before detectable metabolites appear, collection after the detection window, or concentrations below the cutoff can yield a negative result despite exposure. Acute evaluation must proceed according to the patient's condition while additional testing is considered.
Common pitfall: Do not treat a negative screen as medical clearance or proof that a targeted substance was never taken. Neither the reported exposure label nor the laboratory result replaces examination, assessment for co-use, or consideration of medical illness.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder · the-asam-appropriate-use-of-drug-testing-in-clinical-addiction-medicine-full-document.pdf
Develop and implement an individualized plan of care15%
22.Why can conventional buprenorphine initiation precipitate withdrawal?
Buprenorphine binds opioid receptors strongly but activates them less than a full agonist. Premature conventional initiation can displace the full agonist and abruptly reduce activation. The cited sublingual-tablet label requires clear objective signs of moderate opioid withdrawal. Look for dilated pupils, sweating, piloerection, tremor, tachycardia, abdominal cramps, vomiting, or diarrhea. Use a structured clinical withdrawal assessment to document severity and change alongside exposure history. Craving or anxiety alone is insufficient. Slow breathing and depressed responsiveness suggest opioid toxicity rather than readiness for initiation. Specialized low-dose initiation follows a different clinical plan.
Apply it
A patient reports strong craving after recent full-agonist use but has no objective withdrawal findings. Reassess the observable signs and structured severity assessment before conventional initiation; elapsed time alone does not establish moderate withdrawal.
Common pitfall: Neither one isolated symptom nor a usual waiting interval establishes readiness. Do not apply conventional initiation criteria as though they describe specialized low-dose approaches.
DailyMed — Buprenorphine Sublingual Tablets · CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 · SAMHSA — Overdose Prevention and Response Toolkit
23.Which opioid findings make naltrexone unsafe to start?
Naltrexone blocks opioid receptors and can precipitate severe withdrawal in a person who remains opioid-dependent. Current opioid analgesic use, ongoing dependence, and acute opioid withdrawal contraindicate initiation. The oral label recommends at least 7–10 opioid-free days for patients previously dependent on short-acting opioids, including tramadol. After methadone or buprenorphine, vulnerability to precipitated withdrawal may persist for two weeks. Elapsed time alone cannot guarantee readiness; assess the complete exposure history and clinical state. Even a negative urine screen or tolerated naloxone challenge cannot completely exclude risk.
Apply it
A patient seeking alcohol treatment still takes postoperative opioid analgesics. Withhold oral naltrexone pending a coordinated pain and initiation plan. Omitting the next analgesic dose does not meet the recommended opioid-free interval.
Common pitfall: The alcohol-treatment indication does not remove opioid contraindications, and reaching a calendar threshold does not prove that physiological dependence has resolved.
24.How does pregnancy affect opioid use disorder planning?
Pregnancy calls for coordinated addiction and obstetric care rather than automatic discontinuation of opioid use disorder medication. Methadone or buprenorphine treatment is recommended over withdrawal management alone for pregnant patients with opioid use disorder. Untreated illness and return to use carry substantial risks, so treatment planning should support medication access, prenatal care, and ongoing monitoring. Nursing actions include identifying barriers and communicating across services without interpreting pregnancy itself as a reason to withhold effective treatment.
Apply it
A pregnant patient taking buprenorphine asks whether stopping immediately would protect the fetus. Support prompt discussion with the addiction and obstetric teams, explain the value of continuing effective treatment, and assess barriers to consistent prenatal and medication follow-up.
Common pitfall: Equating medication exposure with a reason for abrupt discontinuation ignores the risks of untreated opioid use disorder, destabilization, and return to use during pregnancy.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
25.How do alcohol use disorder medications differ?
Naltrexone can reduce alcohol reward and heavy drinking, but opioid exposure and dependence must be assessed before initiation. Acamprosate supports maintenance of abstinence in patients abstinent at treatment initiation; it is renally eliminated and contraindicated when creatinine clearance is 30 mL/min or less. Disulfiram inhibits acetaldehyde metabolism, causing acetaldehyde to accumulate after alcohol consumption. The resulting reaction can include flushing, vomiting, and hypotension; severe reactions can cause cardiovascular collapse and death. Selection requires attention to treatment goals, contraindications, adherence, and psychosocial support. These medications do not replace treatment of dangerous acute withdrawal.
Apply it
A patient who has achieved alcohol abstinence asks about acamprosate, but creatinine clearance is 25 mL/min. Recognize the contraindication and discuss alternatives with the prescriber. If disulfiram is considered, explain acetaldehyde accumulation and potentially life-threatening reactions, including risks from alcohol-containing products and alcohol consumed up to 14 days after the last dose.
Common pitfall: Treating all alcohol medications as interchangeable overlooks renal contraindications and opioid-related hazards. Describing the disulfiram–alcohol reaction as merely unpleasant understates its potential cardiovascular severity.
NIAAA — Treatment for Alcohol Problems: Finding and Getting Help · DailyMed - ACAMPROSATE CALCIUM tablet, delayed release · DailyMed - DISULFIRAM tablet · DailyMed — Naltrexone Hydrochloride Tablets, USP
26.Which factors determine a safe alcohol withdrawal setting?
Withdrawal placement depends on the risk of complications, current severity, medical and psychiatric stability, and the safety of the recovery environment. Ambulatory care requires appropriate monitoring and the ability to follow the plan; severe symptoms or unstable conditions can require a higher level of care. Prior complicated withdrawal matters even when symptoms are initially modest. Build explicit reassessment and escalation arrangements into the plan instead of assuming that one reassuring encounter establishes safety for the entire course.
Apply it
A patient with prior withdrawal seizures requests home management but lives alone and cannot attend reliable reassessments. Bring these combined risks to the team when selecting the setting rather than basing placement only on today's mild tremor.
Common pitfall: Choosing outpatient management because the patient prefers it, without evaluating complication risk and monitoring feasibility, confuses shared decision-making with an assessment that omits essential safety information.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
27.How should a benzodiazepine taper be individualized?
A benzodiazepine taper should reflect the person's exposure, withdrawal history, co-occurring conditions, and response to dose reductions. Regular long-term use should not be stopped abruptly when physical dependence is likely. Develop the plan collaboratively, monitor symptoms after changes, and slow or pause reductions when clinically significant withdrawal emerges. The purpose is to reduce medication-related harm while minimizing destabilization. A rigid schedule that ignores the patient's response is less appropriate than an adaptable, monitored plan.
Apply it
A patient develops substantial insomnia, tremor, and anxiety after a planned reduction. Communicate the symptom pattern and timing, assess safety, and support review of the taper pace rather than insisting that the original schedule proceed unchanged.
Common pitfall: Interpreting every withdrawal symptom as nonadherence or drug-seeking prevents useful adjustment and may increase the likelihood of an unsafe abrupt stop or disengagement from care.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
28.Why prioritize contingency management for stimulant use disorder?
Contingency management uses meaningful incentives linked to defined, verified behaviors to increase the likelihood that those behaviors recur. The ASAM/AAAP guideline identifies it as a primary component of stimulant use disorder treatment, usually alongside other psychosocial interventions. The plan must specify the target behavior, verification method, and reinforcement delivery. Simply praising improvement or offering an unrelated reward lacks the structured contingency that defines the intervention and supports evaluation of whether it is being implemented faithfully.
Apply it
A patient with stimulant use disorder wants help attending treatment consistently. Work with the program to define attendance targets and verification, explain the incentive arrangement clearly, and pair the approach with other appropriate behavioral treatment and recovery support.
Common pitfall: Calling any encouragement contingency management overlooks its essential structure: an explicit connection between a measurable behavior and a predictable reinforcing consequence delivered through the treatment program.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
29.How should alcohol and psychiatric treatment be coordinated?
Alcohol use disorder and psychiatric conditions can reinforce one another and require coordinated assessment and treatment. Clarify symptom chronology, current risk, medications, and each service's responsibilities, while avoiding a blanket requirement that one disorder be resolved before the other receives care. Benzodiazepines can be appropriate for acute alcohol withdrawal, but that role does not establish them as routine long-term treatment for co-occurring anxiety in someone with alcohol use disorder. Reassess benefits and risks over time.
Apply it
A patient with alcohol use disorder and persistent panic symptoms receives separate instructions from two clinics. Arrange communication about diagnosis, medication risks, and follow-up responsibilities so that ongoing psychiatric treatment and alcohol care proceed through a coherent plan.
Common pitfall: Extending a medication used briefly for withdrawal into indefinite anxiety treatment without reassessment confuses an acute indication with a different long-term clinical decision and risk profile.
NIAAA — Alcohol Use Disorder and Common Co-occurring Mental Health Conditions
30.How does combination nicotine replacement address different cravings?
Combination nicotine replacement commonly pairs a nicotine patch with gum or a lozenge. The patch provides steadier nicotine delivery, while the shorter-acting product can address breakthrough cravings. This complementary pattern can improve cessation success compared with using one nicotine replacement product alone. Assess product suitability, teach correct use, and include behavioral counseling. Continued cravings on a patch do not automatically mean treatment has failed; they may identify a need to review use and add an appropriate complementary product.
Apply it
A patient using a nicotine patch reports strong cravings during work breaks despite consistent use. Review technique and suitability, discuss gum or lozenges for breakthrough cravings, and connect the medication plan with counseling and a strategy for those breaks.
Common pitfall: Assuming a patch should eliminate every craving can lead to premature abandonment of treatment rather than an appropriate review of adherence, technique, and combination options.
Educate and promote behavioral change15%
31.How does motivational interviewing work with ambivalence?
Motivational interviewing explores ambivalence through collaboration rather than argument. Ask open questions, reflect the patient's perspective, and elicit personally meaningful reasons for change. A discrepancy between current drinking and an important goal can help the patient examine choices without the nurse imposing a conclusion. The decision-making cue is mixed motivation: a person can value alcohol's perceived benefits while also wanting fewer consequences. Respond to both sides while supporting the patient's capacity to choose.
Apply it
A patient says alcohol helps with stress but is damaging relationships with children. Invite discussion of both experiences and ask how drinking fits with the kind of parent the patient wants to be, without insisting on an immediate commitment.
Common pitfall: Arguing that the patient must admit alcohol is entirely harmful often strengthens defensive explanations and reduces the opportunity to hear the patient's own reasons for change.
32.Which reflections encourage a patient's reasons for change?
Reflective listening returns the meaning or feeling in a patient's statement rather than immediately correcting, questioning, or advising. When a patient voices reasons, ability, desire, or need for change, an accurate reflection can help develop that change talk. Reflections should remain faithful to what the patient expressed rather than exaggerating readiness. Follow with an invitation to elaborate when useful. The mechanism is focused attention to the patient's own motivation, while preserving autonomy and reducing an adversarial exchange.
Apply it
A patient says, 'I am tired of losing whole weekends to drinking.' Reflect the wish to regain time and ask what a better weekend would look like, allowing the patient to develop the significance of the concern.
Common pitfall: Turning a tentative concern into 'You are ready to stop forever' overstates commitment and may cause the patient to retreat from a useful discussion about change.
33.Why must overdose education address reduced opioid tolerance?
Opioid tolerance can decrease during abstinence or substantially reduced exposure. Returning to a previously tolerated amount can then produce overdose because the person's current physiological tolerance is lower. Teach this risk during transitions such as withdrawal completion, hospitalization, or other interruptions in use. Include access to naloxone, recognition of slowed breathing, and connection to ongoing treatment. A period without opioid use is clinically meaningful, but it does not establish protection from overdose after return to use.
Apply it
A patient leaving a withdrawal program says the previous amount will be safe if use resumes. Explain the loss-of-tolerance risk, review naloxone access and emergency response, and strengthen the connection to ongoing opioid use disorder treatment before discharge.
Common pitfall: Describing completed withdrawal as protection from future overdose overlooks the increased vulnerability created when reduced tolerance is followed by a return to a former amount.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 · SAMHSA — Overdose Prevention and Response Toolkit
34.How should families be taught to respond to opioid overdose?
Teach families to recognize unresponsiveness and abnormal breathing, call emergency services immediately, give naloxone according to directions, and provide indicated breathing or resuscitative support. Explain that gasping is abnormal breathing and that naloxone does not replace support of breathing and circulation. Families should follow emergency dispatcher instructions and their responder training. They should know how to obtain additional help, locate their naloxone, and continue observing the person because improvement can be temporary. Neither administering naloxone nor awaiting its effect should delay emergency action.
Apply it
Ask the partner to rehearse finding the patient unresponsive and gasping: call emergency services on speakerphone, follow dispatcher instructions for resuscitative support, and have another person obtain naloxone and an AED if available. Practise device use, discuss repeat medication according to directions, and explain why improvement does not cancel emergency evaluation.
Common pitfall: Teaching only naloxone device operation leaves responders unprepared to address inadequate breathing. Telling families to wait for the medication to work can delay lifesaving action.
35.Why discuss alcohol and other sedatives during benzodiazepine education?
Benzodiazepines can combine with alcohol, opioids, and other central nervous system depressants to increase sedation and respiratory risk. Ask about actual co-use without assuming prescribed drugs are automatically safe together. Teach the patient to disclose all sedating substances and to seek review before medication changes. At the same time, explain that abruptly stopping a regularly used benzodiazepine can cause dangerous withdrawal. Effective education addresses both interaction hazards and the need for a coordinated discontinuation plan.
Apply it
A patient taking a daily benzodiazepine plans to stop it suddenly after learning that alcohol co-use is risky. Explain both hazards and arrange prompt medication review so that reducing interaction risk does not create unmanaged withdrawal.
Common pitfall: Giving only the message 'stop the sedative' can produce an abrupt discontinuation, while reassurance based solely on a prescription overlooks additive depressant effects and overdose risk.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
36.How should contingency management be explained to patients?
Explain contingency management as a transparent behavioral treatment in which specified achievements produce agreed incentives. The patient should understand the target, how it is verified, when reinforcement occurs, and what happens when a target is missed. Timely, consistent reinforcement strengthens the relationship between behavior and consequence. Frame participation respectfully and avoid moral judgments about earning care. Essential treatment and supportive engagement remain distinct from the incentive arrangement, so a missed target does not justify humiliation or abandonment.
Apply it
A patient worries that missing one stimulant-negative test means expulsion from treatment. Review the program's actual incentive rules, clarify continued access to clinical care, and explain how the next achievable target supports renewed participation and progress.
Common pitfall: Using incentives as punishment or withholding essential care after a missed target undermines the therapeutic purpose and confuses reinforcement with coercion or a judgment of worth.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
37.What should cannabis driving counseling make concrete?
Cannabis driving counseling should connect impairment to a specific transportation plan. Explain that slowed reactions, altered perception, and reduced coordination can compromise driving even when a person feels capable. Alcohol co-use adds risk. Effects vary, so a universal waiting interval cannot guarantee driving safety. Help the patient choose alternatives before use, such as a designated driver, public transport, or remaining in a safe location.
Apply it
A patient asks for a guaranteed number of hours after cannabis use when driving becomes safe. Explain the variability in impairment and help arrange a transportation plan that does not depend on a promised clearance time or subjective confidence.
Common pitfall: Offering a precise universal waiting period can falsely reassure patients despite differences in products, exposure, individual response, and concurrent alcohol use that affect actual impairment.
38.How does rehearsal turn alcohol refusal advice into a usable skill?
A coping skill requires a specific response that the patient can perform in a likely situation. Identify who offers alcohol, the setting, and the pressure involved. Help the patient choose a brief refusal, practise saying it, and plan an alternative activity or exit if pressure continues. Give feedback and repeat the rehearsal until the response fits the patient's circumstances. This builds a behavioral alternative to accepting a drink rather than relying only on an intention to avoid drinking.
Apply it
A patient expects coworkers to offer alcohol after a shift. Rehearse a direct refusal, arrange a nonalcoholic choice, and identify how the patient will leave if coworkers persist. Ask the patient to practise the response aloud.
Common pitfall: A list of coping suggestions does not establish that the patient can use a selected skill under social pressure.
39.How does patient choice support trauma-informed education?
Trauma-informed communication emphasizes safety, transparency, collaboration, and empowerment through voice and choice. Explain what an assessment involves, why information is needed, and what choices are available before proceeding. Education becomes more usable when the patient retains a meaningful role and can identify concerns. This approach does not require eliciting a detailed trauma narrative. The discriminating question is whether the interaction increases understanding and participation without unnecessarily reproducing helplessness or loss of control.
Apply it
A patient becomes tense when a nurse begins asking sensitive questions in a busy area. Offer a private setting, explain the assessment's purpose, and discuss pacing and available choices before continuing with information needed for safe care.
Common pitfall: Requiring a detailed trauma disclosure as proof of engagement can undermine safety and choice; trauma-informed practice can guide care even when the patient shares no history.
CDC/SAMHSA — Six Guiding Principles to a Trauma-Informed Approach
Care management, treatment, and evaluation throughout the recovery continuum (including special populations)35%
40.How do methadone and buprenorphine support ongoing opioid treatment?
Methadone is a full opioid agonist, while buprenorphine is a partial opioid agonist. Both can suppress withdrawal and cravings and support ongoing treatment for opioid use disorder. Their therapeutic role is different from the antagonist action of naltrexone and the emergency reversal role of naloxone. Evaluate response through symptoms, functioning, safety, and engagement rather than assuming continued medication means treatment failure. Medication selection and monitoring should reflect the patient's clinical circumstances and preferences.
Apply it
A patient says buprenorphine is unsuccessful because it is still needed to prevent withdrawal. Explain its maintenance role and review craving control, daily functioning, medication safety, and the patient's goals with the treating team before judging effectiveness.
Common pitfall: Using medication discontinuation as the sole definition of success disregards the intended maintenance benefit and can pressure a stable patient into an unnecessary treatment interruption or loss of care.
41.How should return to opioid use change ongoing care?
Return to opioid use calls for reassessment of treatment effectiveness, overdose risk, adherence barriers, and unmet needs. It should not automatically lead to dismissal from care. Explore what preceded use and whether medication access, cravings, psychiatric symptoms, or social instability contributed. Strengthen treatment and harm-reduction supports while maintaining engagement. The useful distinction is between a finding that signals the need to adjust care and a moral judgment that excludes the person from potentially lifesaving treatment.
Apply it
A patient receiving opioid use disorder treatment reports using opioids after losing housing. Assess immediate safety and medication access, explore the circumstances, and coordinate housing and treatment supports rather than ending care solely because use recurred.
Common pitfall: Discharging a patient for recurrence can remove treatment during a high-risk period and prevents assessment of the barriers that contributed to the event and remain unresolved.
42.Why is withdrawal completion insufficient opioid use disorder treatment?
Withdrawal management addresses the immediate physiological transition away from opioids but does not by itself treat the ongoing disorder. Without continuing treatment, patients remain vulnerable to return to use and overdose, especially after tolerance decreases. Discharge planning should connect the patient with evidence-based medication treatment, follow-up, and naloxone. The discriminating outcome is not simply absence of withdrawal at discharge; it is whether the patient has an accessible, sustained treatment pathway after the acute episode ends.
Apply it
A patient completes opioid withdrawal and has no scheduled follow-up. Before discharge, work to establish medication treatment access, identify transportation or payment barriers, and review overdose response rather than considering symptom resolution a complete treatment plan.
Common pitfall: Treating detoxification as a cure leaves the chronic disorder and post-withdrawal overdose vulnerability insufficiently addressed, even when the immediate physiological withdrawal episode has resolved successfully.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
43.How should pain care remain coordinated during opioid treatment?
A patient with opioid use disorder can also have legitimate acute or chronic pain requiring treatment. Coordinate pain and addiction care so that clinicians understand current medication, overdose risks, and the consequences of unplanned treatment interruption. Use an individualized approach that includes appropriate nonopioid and nonpharmacological options and specialist collaboration when needed. Avoid assuming that opioid use disorder invalidates pain reports or that an unrelated procedure automatically requires discontinuation of effective opioid use disorder treatment.
Apply it
A patient stable on buprenorphine is scheduled for surgery and receives conflicting medication instructions. Facilitate communication among the surgical, anesthesia, and addiction teams so pain treatment and continuity of opioid use disorder care are addressed together.
Common pitfall: Uncoordinated medication changes can destabilize recovery or leave pain undertreated; a history of opioid use disorder does not eliminate the need for a credible pain assessment.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
44.Why should benzodiazepine use not automatically end opioid medication treatment?
Concurrent benzodiazepine and opioid exposure increases sedation and overdose risk, but benzodiazepine use alone is not a reason to withhold or suspend methadone or buprenorphine treatment. Coordinate prescribing, assess respiratory and withdrawal risks, provide overdose education, and address benzodiazepine use through an individualized plan. The decision balances interaction hazards against the harms of untreated opioid use disorder. Managing one medication risk should not create a separate, avoidable interruption in effective treatment for another disorder.
Apply it
A patient on methadone discloses nonprescribed benzodiazepine use and fears losing treatment. Assess safety, inform the treating team, and support coordinated risk reduction and benzodiazepine management while maintaining access to opioid use disorder care and follow-up.
Common pitfall: Automatically stopping opioid medication because of benzodiazepine use removes a protective treatment without resolving the sedative exposure or the risks associated with untreated opioid use disorder.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
45.Which outcomes guide the duration of opioid medication treatment?
Opioid use disorder medication has no universal maximum treatment duration. Review benefit, adverse effects, cravings, return to use, functioning, access, and patient preferences over time. Continued stability can demonstrate that treatment is working rather than prove that medication is no longer needed. If discontinuation is being considered, the plan should address recurrence and overdose risks and preserve access to care. Avoid using an arbitrary calendar endpoint as a substitute for individualized evaluation.
Apply it
A patient functioning well after a year of buprenorphine worries that treatment must end at the next anniversary. Explain that duration is individualized and help review benefits, risks, preferences, and continued monitoring with the prescribing team.
Common pitfall: Treating a fixed treatment anniversary as a mandatory stopping point ignores the patient's response and may disrupt a regimen that continues to reduce harm and support functioning.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
46.How should alcohol withdrawal care lead into continuing treatment?
Alcohol withdrawal management prevents or treats acute complications, but it is not a complete treatment for alcohol use disorder. Use the episode to discuss ongoing medication, behavioral treatment, recovery supports, and follow-up. Begin planning while the patient is engaged rather than waiting until discharge, and adapt discussions to cognitive and medical readiness. Successful transition means more than providing a resource list: the patient should understand the next step and have a feasible route to obtain it.
Apply it
A patient finishes medically managed alcohol withdrawal and asks what happens next. Review treatment preferences, arrange a specific follow-up connection, and address practical barriers such as transportation instead of limiting discharge care to resolved withdrawal symptoms.
Common pitfall: Assuming an uncomplicated withdrawal episode resolves alcohol use disorder overlooks the continuing mechanisms and circumstances that can sustain drinking after the acute symptoms have ended.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management · NIAAA — Treatment for Alcohol Problems: Finding and Getting Help
47.Why reassess mood and anxiety during alcohol recovery?
Mood, anxiety, sleep, and alcohol symptoms can change at different rates during treatment. Repeated assessment helps distinguish improvement associated with reduced drinking from persistent psychiatric illness requiring its own care. Continue assessing suicide risk and functional impairment rather than waiting for diagnostic certainty. Coordinate treatment so that psychiatric symptoms do not become an unaddressed driver of drinking and alcohol use does not undermine psychiatric recovery. A single early assessment cannot establish the full longitudinal pattern.
Apply it
A patient drinks less after treatment but continues to experience disabling depression and hopelessness. Reassess safety, document the symptom trajectory, and coordinate psychiatric follow-up rather than assuming reduced alcohol use will inevitably resolve every mental health symptom.
Common pitfall: Attributing persistent symptoms entirely to alcohol can delay necessary treatment, while ignoring changes during recovery can also prevent refinement of the psychiatric assessment and care plan.
NIAAA — Alcohol Use Disorder and Common Co-occurring Mental Health Conditions
48.Which alcohol treatment outcomes belong in shared review?
Evaluate alcohol treatment using drinking patterns, alcohol-related consequences, health, functioning, engagement, and the patient's agreed goals. Abstinence may be an important goal, but a binary label alone can hide meaningful changes or continuing hazards. Review whether the selected medication and behavioral supports are acceptable and usable. The purpose of outcome monitoring is to guide treatment adjustments, not merely to categorize the patient. New medical or safety information may also require revisiting the original goals.
Apply it
A patient has fewer heavy-drinking days and better work attendance but still has alcohol-related falls. Acknowledge the improvements while addressing the continuing injury risk and reviewing whether the current goals and treatment intensity need adjustment with the patient.
Common pitfall: Calling the entire treatment successful because drinking decreased can miss persistent harm; calling it wholly unsuccessful can erase useful progress and discourage continued engagement with care.
NIAAA — Treatment for Alcohol Problems: Finding and Getting Help · NIAAA — Combined Behavioral Intervention Manual
49.How can a drinking episode inform relapse-prevention work?
A return-to-drinking episode can be examined for antecedents, expectations, decisions, consequences, and missed coping opportunities. This functional analysis identifies specific points where a different response could be practiced. Ask what happened before the episode and what the patient noticed, rather than reducing the event to lack of motivation. Translate the findings into a concrete coping plan, such as responding to interpersonal stress or leaving a high-risk setting, and review how the revised plan works.
Apply it
A patient drank after an argument and an unplanned stop at a familiar bar. Map the sequence together and rehearse an alternative response to the argument and route home, then arrange follow-up to assess whether the plan is usable.
Common pitfall: Offering only a stronger warning to avoid alcohol fails to identify the episode's sequence and leaves the patient without a specific behavior to practice next time.
50.When can a supportive person strengthen alcohol treatment?
A willing, appropriate supportive person can help with encouragement, treatment participation, and recovery-related changes when involvement is acceptable to the patient. Clarify the supporter's role and the patient's preferences rather than assuming family involvement is automatically helpful. Support should reinforce the patient's goals and coping efforts without becoming surveillance or coercion. Explore relationship safety and practical usefulness before incorporating another person into the plan, and continue to preserve the patient's voice in treatment decisions.
Apply it
A patient wants a trusted sibling involved in alcohol treatment appointments. Discuss what information and tasks the patient wants shared, agree on useful support such as transportation or encouragement, and revisit whether the arrangement remains helpful over time.
Common pitfall: Inviting relatives automatically can undermine trust or introduce unsafe dynamics; effective involvement depends on the patient's preferences, relationship context, and a clear, agreed supportive role.
51.How should symptoms be interpreted during a benzodiazepine taper?
Symptoms during tapering may represent withdrawal, recurrence of the original condition, or another problem. Their timing relative to dose reductions, pattern, severity, and response to adjustments help interpretation. Monitor sleep, anxiety, functioning, and safety at each stage, and communicate significant changes to the prescribing team. Avoid assuming that every symptom proves the medication must be continued indefinitely or that every symptom should be endured without adjustment. The plan remains responsive to the person's course.
Apply it
A patient develops new tremor and marked anxiety shortly after each benzodiazepine reduction but improves when reductions pause. Record the timing and functional effects, assess for complications, and support reassessment of the taper rather than assigning a premature explanation.
Common pitfall: Automatically labeling symptoms as the original anxiety disorder can miss withdrawal; automatically calling every symptom withdrawal can overlook a co-occurring condition requiring its own treatment.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
52.Why review proposed substitute sedatives during benzodiazepine reduction?
Reducing one sedative does not eliminate the need to assess misuse and interaction risks from other medications. The benzodiazepine tapering guideline notes that gabapentin and pregabalin can have misuse potential and should not be reflexively prioritized as adjuncts. Review the indication, expected benefit, actual use, and concurrent depressants when another medication is proposed. A substitution should solve a defined clinical problem, not merely transfer dependence or risk to a different sedating drug.
Apply it
A patient tapering a benzodiazepine requests a friend's pregabalin to manage discomfort. Discourage sharing medication, assess the symptoms and current substances, and arrange review of appropriate options instead of treating a different drug class as automatically low risk.
Common pitfall: Assuming every nonbenzodiazepine sedating medication is a harmless replacement bypasses assessment of misuse potential, interactions, and whether the proposed treatment addresses the patient's actual symptoms.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
53.How can cognitive behavioral treatment complement stimulant incentives?
Contingency management reinforces defined behaviors, while cognitive behavioral treatment develops skills for recognizing triggers, examining thoughts, and choosing alternative responses. The ASAM/AAAP guideline supports combining contingency management with additional psychosocial approaches, including cognitive behavioral therapy. Their functions are complementary rather than interchangeable. Evaluate whether the patient can apply coping skills outside the incentive setting as well as whether the target behavior occurs within it. A combined plan addresses both immediate reinforcement and broader recovery situations.
Apply it
A patient attends stimulant treatment reliably under an incentive program but struggles with cravings during conflict at home. Maintain the effective attendance support while adding skills work on conflict-related triggers, coping responses, and practice outside treatment sessions.
Common pitfall: Assuming successful attendance incentives automatically teach every coping skill can leave predictable high-risk situations unaddressed once the patient is outside the structured treatment environment and support system.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
54.Why monitor psychiatric symptoms beyond early stimulant withdrawal?
Stimulant-related depression, anxiety, insomnia, paranoia, or psychotic symptoms may persist beyond the initial intoxication episode. Repeated assessment should consider symptom severity, expected time course, previous psychiatric history, and functional effects. Treat clinically significant symptoms while refining the diagnosis; do not assume that every persistent symptom is either permanent primary illness or harmless withdrawal. Ongoing suicide assessment is especially important when depression or hopelessness emerges. Care should track the changing clinical picture rather than a single early label.
Apply it
A patient several weeks into stimulant recovery continues to sleep poorly and reports paranoia interfering with appointments. Reassess safety and symptom history, communicate the persistence and impact, and coordinate psychiatric care rather than assuming time alone will resolve the problem.
Common pitfall: Dismissing persistent psychiatric symptoms as an inevitable crash can delay treatment, while making an irreversible diagnostic conclusion from the first intoxication encounter can also misdirect care.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
55.Why include opioid overdose prevention in stimulant recovery care?
People using nonmedical stimulants can encounter opioids through contamination or intentional co-use, so overdose prevention should not be restricted to patients identifying opioids as their primary substance. Discuss naloxone access, recognition of respiratory depression, emergency response, and available drug-checking services where applicable. Explain that naloxone reverses opioid effects rather than stimulant toxicity itself. This distinction supports a broad prevention plan without falsely reassuring the patient that naloxone treats every complication of an unknown drug supply.
Apply it
A patient using cocaine declines naloxone because opioids are not intentionally used. Explain potential unexpected opioid exposure and review why slow or absent breathing after any unknown supply warrants an opioid-overdose response alongside emergency medical evaluation.
Common pitfall: Restricting naloxone education to self-identified opioid users misses unexpected exposure; presenting naloxone as treatment for stimulant hyperthermia or cardiac toxicity creates a different and unsafe misunderstanding.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder · SAMHSA — Overdose Prevention and Response Toolkit
56.What does a reactive hepatitis C antibody result establish?
A reactive hepatitis C antibody result can represent current infection, resolved infection, or biologic false positivity. HCV RNA testing identifies current infection, and reflex RNA testing after a reactive antibody result helps complete the diagnostic sequence. Reactive antibody with detectable RNA indicates current infection and requires linkage to care; reactive antibody with undetectable RNA generally indicates no current infection. If distinguishing resolved infection from biologic false positivity is needed, testing with another HCV antibody assay can help. Interpret the full sequence and exposure history rather than antibody reactivity alone.
Apply it
A patient assumes a reactive antibody result proves active infection. Verify reflex RNA testing and explain all three possible interpretations. If RNA is undetectable, explain that there is generally no current infection; another antibody assay may help clarify resolved infection versus false positivity when that distinction is needed.
Common pitfall: Calling every reactive antibody result proof of exposure overlooks biologic false positivity. Diagnosing active infection from antibody alone also bypasses the RNA result needed to identify current infection.
57.When can a negative hepatitis C antibody test miss infection?
Possible HCV exposure within the preceding six months warrants HCV RNA testing regardless of the antibody result. HCV RNA usually becomes detectable approximately 1–2 weeks after exposure, whereas antibodies usually take 8–11 weeks. A negative antibody result can therefore miss early infection. Testing immediately after exposure can also precede detectable RNA, so interpret negative results against the exposure date and arrange appropriate follow-up. Ongoing exposure may require periodic testing; a single negative result does not cover exposures occurring afterward.
Apply it
A patient shared injection equipment three weeks ago and has a negative antibody result today. Arrange HCV RNA testing because the possible exposure occurred within six months. If exposure occurred only several days ago, explain that even RNA may not yet be detectable and ensure follow-up testing accounts for that timing.
Common pitfall: Treating a negative antibody result as definitive after a recent exposure ignores the antibody window period. Treating RNA testing performed immediately after exposure as conclusive ignores its earlier but still present detection window.
58.Which hepatitis prevention services belong in continuing addiction care?
Hepatitis prevention combines vaccination where available, sterile equipment access, testing, and linkage to treatment. People who use or inject drugs should be assessed for hepatitis A and B vaccination needs; there is no hepatitis C vaccine. Syringe services can provide sterile supplies and connections to testing, vaccination, and substance use treatment. These services remain useful even when abstinence is not the patient's immediate goal. Prevention and recovery treatment can proceed together rather than being made conditional on one another.
Apply it
A patient continues injecting while attending treatment and has uncertain vaccination records. Review hepatitis A and B vaccination needs, connect the patient with sterile equipment services, and arrange appropriate hepatitis testing without requiring abstinence before preventive care.
Common pitfall: Offering vaccination as if it prevents hepatitis C creates false reassurance; withholding preventive services until abstinence delays opportunities to reduce infection risk during ongoing treatment and engagement.
59.How should process addictions enter continuing SUD care?
Ask about behavioral addictions and compulsions alongside substance use. Document the behavior, impaired control, distress, and effects on functioning; frequency alone does not establish a diagnosis. Explore whether the behavior interferes with housing, relationships, treatment attendance, or the patient's recovery goals. Coordinate further assessment when gambling or another behavior contributes to unmet clinical or practical needs.
Apply it
A patient reports reduced stimulant use but spends rent money gambling. Assess housing stability and emotional safety, arrange a gambling-focused assessment, and include financial consequences and treatment participation in follow-up. Continue effective substance use treatment while addressing the additional concern.
Common pitfall: Substance outcomes alone can conceal continuing behavioral harm. Automatically labeling every frequent activity an addiction also bypasses assessment of control, consequences, and impairment.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder · CARN Test Specifications (Blueprint) — Implemented 2026
60.How should adolescent and young adult needs shape stimulant recovery services?
Use developmentally appropriate care and age-specific treatment or support services when available. Assess school participation, home circumstances, transportation, and co-occurring concerns such as ADHD or eating disorders. Match the treatment plan to the young person's functioning, priorities, and available supports. Lack of a specialized program should not delay treatment; continue accessible care while coordinating suitable services.
Apply it
A young adult misses appointments because they conflict with school and reliable transportation is unavailable. Coordinate feasible scheduling and appropriate youth services, discuss acceptable support-person involvement, and review whether the revised arrangements improve attendance while current treatment continues.
Common pitfall: An adult service schedule may create an avoidable engagement barrier. Interpreting missed visits as unwillingness without examining developmental and practical needs can lead to an ineffective plan.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the practice-domain weights to organize study, then cross-check the patient-problem matrix; opioid and alcohol topics together account for just over half of that second axis.
- Distinguish screening, diagnosis, physiological dependence, intoxication, withdrawal, and treatment response rather than treating them as interchangeable findings.
- Practise urgent decisions using respiratory status, attention, temperature, chest symptoms, withdrawal history, and current suicidal thinking. Distinguish delirium assessment, agitation and sedation monitoring, and withdrawal severity monitoring.
- Connect medication mechanisms to decisions: antagonist-precipitated withdrawal, objective moderate withdrawal before conventional buprenorphine initiation, naltrexone opioid-free intervals, sedative interactions, and maintenance treatment continuity.
- Give the largest study block to continuing care: engagement after recurrence, integrated medical and psychiatric care, prevention, process-related harms, and evaluation of patient-defined outcomes. Use psychosocial findings to make plans accessible.
- Use the full official outline to extend beyond this selection, including the complete range of hallucinogen presentations, process addictions, medication misuse, and special-population needs.
A practical preparation plan
1. Map the two blueprint axes
Create a study grid with the five practice domains as rows and seven patient-problem categories as columns. Place each learning objective in the grid so that strong knowledge of one substance does not conceal a weak nursing function.
2. Build discriminating clinical pairs
Compare opioid dependence with opioid use disorder, withdrawal hallucinations with delirium, HCV antibody with RNA, and current stabilization with sustained safety. State the decisive finding and the nursing action that follows.
3. Rehearse acute decisions aloud
For overdose, complicated withdrawal, stimulant chest pain, hyperthermia, and suicidal thoughts, describe the immediate problem, required assessment, escalation, and reassessment. Explain why a tempting routine response would be insufficient.
4. Link mechanisms to care plans
Explain objective moderate withdrawal before conventional buprenorphine initiation, the opioid-free intervals and remaining uncertainty before naltrexone, individualized benzodiazepine tapering, pregnancy-related treatment continuity, and combination nicotine replacement.
5. Practise continuing-care review
Use mini-cases to revise a plan after return to use, missed visits, persistent depression, ongoing infection exposure, or medication-access problems. Include treatment history, functioning, recovery environment, supports, housing, transportation, patient priorities, and a measurable follow-up outcome.
6. Review errors against evidence
Complete the 20 questions, explain every option, and revisit the relevant clinical reference for missed distinctions. Use the flashcards for spaced recall, then return to the official outline to identify material beyond this guide.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ANCB — Home
- ANCB — Statistics & Studies
- C-NET — Certified Addictions Registered Nurse
- CARN Examination Handbook — Revised January 2026
- CARN Test Specifications (Blueprint) — Implemented 2026
- CDC — Opioid Use Disorder: Diagnosis
- NIAAA — Screen and Assess: Use Quick, Effective Methods
- CDC — Viral Hepatitis Among People Who Use or Inject Drugs
- SAMHSA — Overdose Prevention and Response Toolkit
- ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
- ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
- NIMH — Adult Outpatient Brief Suicide Safety Assessment Guide
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
- DailyMed — Naltrexone Hydrochloride Tablets, USP
- Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
- NIAAA — Combined Behavioral Intervention Manual
- CDC — How to Combine Quit Smoking Medicines
- CDC — Cannabis and Driving
- DailyMed — Buprenorphine Sublingual Tablets
- CDC — Clinical Screening and Diagnosis for Hepatitis C
- CDC/SAMHSA — Six Guiding Principles to a Trauma-Informed Approach
- NIAAA — Alcohol Use Disorder and Common Co-occurring Mental Health Conditions
- NIAAA — What Is a Standard Drink?
- NIAAA — Treatment for Alcohol Problems: Finding and Getting Help
- CDC — Opioid Use Disorder: Treating
- DailyMed - ACAMPROSATE CALCIUM tablet, delayed release
- DailyMed - DISULFIRAM tablet
- the-asam-appropriate-use-of-drug-testing-in-clinical-addiction-medicine-full-document.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.